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Abstract 
Mannose-binding lectin (MBL2) is an important pattern recognition molecule that identifies and binds to specific 
sugar molecules on the surface of pathogens thereby activating its destruction by the immune system. Samples 
for study were recruited from Uyo metropolis of Akwa Ibom state in Nigeria. In this study, levels of MBL2 was 
measured by enzyme-linked immunosorbent assay in tuberculosis patients and healthy individuals to determine 
if the immune protein protects against tuberculosis infection. MBL2 levels in tuberculosis patients and healthy 
controls were 14.0ng/ml ± 13.9 and 19.9ng/ml ± 18.5 respectively. The results from the study showed that there 
was no association in MBL2 levels between tuberculosis and controls (p=0.107) as well as between the different 
sub-groups. Therefore, MBL2 is not a contributory factor in resistance against tuberculosis in the population 
under study. 
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1. Introduction 
Mannose-binding lectin (MBL), also known as mannose-binding protein, mannan-binding protein and core-
specific lectin (Turner, 1996) is classified among the collectin protein family characterized by the possession of a 
collagenous region and a lectin domain (Auriti et al., 2017). It is a pattern recognition molecule which 
recognizes and binds to exposed specific sugar surfaces of microorganisms thereby triggering immune response 
(Takahashi et al., 2006).  
The C-type liver serum lectin plays a key role in innate immune response (Eisen & Minchinton, 2003). As 
an acute phase protein (Ezekowitz et al., 1991), the Human mannan-binding protein immunologically responds 
as an acute phase reactant shown by an increase  in its serum concentration during acute phase response - a 
systemic reaction to an inflammatory response (Thiel et al., 1992). MBL acts against a wide variety of micro-
organisms including bacteria (aerobic and anaerobic), fungi and viruses as well as parasites (Neth et al., 2000; 
Townsend et al., 2001; Ezekowitz et al., 1989; Ying et al., 2004). This underlines the role of MBL in first-line 
immune defense against pathogens. The binding of the MBL to microbial surface carbohydrates activates the 
lectin complement pathway and enhances opsonophagocytosis (Neth et al., 2002). 
Structural mutations in exon 1 and promoter polymorphisms in the MBL-2  gene can result in differential 
MBL levels in humans (Eisen & Minchinton, 2003). Three point mutations at codon 54, 57 and 52 of the MBL-2 
gene, associated with low level serum MBL (Sumiya et al., 1991) has been found to be of high frequency among 
the world populations (Lipscombe et al., 1993).Several studies have reported that polymorphisms that produce 
low level MBL provides protection against tuberculosis (Mombo et al., 2003; Cosar et al., 2008; Capparelli et al., 
2009; Singla et al., 2012) while others conclude that these polymorphisms confer susceptibility to TB (Alagarasu 
et al., 2007; Shen et al., 2020). MBL deficient individuals are more susceptible to infections. However, the 
susceptibility is more pronounced among individuals homozygous for the mutant alleles (Mombo et al., 2003). 
MBL level deficiency has been shown to be associated with increased susceptibility to various infectious 
diseases such as sepsis, meningococcal disease, aspergillosis as well as invasive pneumococcal infections 
(Peterslund et al., 2001; Eisen & Minchinton, 2003; Lambourne et al., 2009). It has been suggested that the best 
way to unravel the association between MBL levels and predisposition to tuberculosis could be through direct 
measurement of MBL levels in blood (Denholm et al., 2010). An earlier study that deployed this method 
suggested that high level MBL may play a considerable disadvantageous role in tuberculosis susceptibility, due 
to their findings that there was a significantly higher MBL level in tuberculosis infected individuals than non-
infected individuals (Bonar et al., 2004). 
No study has been conducted or reported on the association of mannose binding lectin with tuberculosis in 
this population. Therefore, this study set out to investigate the association of MBL levels with predisposition to 
tuberculosis infection among the population of Uyo Metropolis, Akwa Ibom State in Nigeria by directly 
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measuring the MBL levels in the serum of tuberculosis patient samples and healthy individuals as controls.  
 
2. Materials And Methods 
The study recruited 60 tuberculosis patients as cases from St. Luke’s Hospital, Anua, Uyo and  60 healthy 
individuals were recruited from the University of Uyo Teaching Hospital  as controls. Healthy individuals were 
defined as those who did not have any disease condition.  Ethical approval was obtained from the two hospitals 
and blood samples were collected from cases and control in line with ethical guidelines.  
Blood samples were centrifuged to obtain serum/plasma for subsequent application in Enzyme-linked 
Immunosorbent assay (ELISA). The ELISA reagents were purchased from OriGene Technologies. The MBL 
concentrations in serum/plasma was measured by ELISA technique in line with manufacturer’s protocols. 
Samples with outlier values were excluded from further analysis. 
Data obtained was subjected to statistical tests to determine the level of association of MBL concentration 
with tuberculosis susceptibility. T-test and ANOVA were used to assess the level of association between the 
different groups tested. Significant difference was based on a cut off mark of p ≤ 0.05   
 
3. Results 
The assay result showed that the mean levels of MBL2 in healthy controls was 19.9ng/ml ± 18.52 while that of 
tuberculosis cases was 14.0ng/ml ± 13.92 (Table 1). The t-test analysis of MBL2 levels in tuberculosis patients 
and healthy controls showed no significant difference between the two groups (p= 0.107).  
The sample population was also assessed based on gender. The population size of males was 14 while that 
of the females was 26 for healthy controls. Additionally, the males constituted 18 cases whereas females made 
up 22 cases for tuberculosis. The mean MBL2 levels for male healthy controls was 15.5 ± 15.9 while that of 
male tuberculosis patients was 12.3 ± 13.93. The female population of our study subjects had mean MBL2 levels 
of 15.5 ± 14. 12 and 20.9 ± 18.80 for TB patients and healthy controls respectively (Table 1). There was no 
significant difference in mean MBL2 levels between male and female healthy controls (p= 0.404When the male 
and female tuberculosis cases were compared statistically, there was no significant difference between them 
(p=0.534). Figure 1 shows the mean distribution of MBL2 levels across the study populations. 
The MBL2 levels in sample population was further stratified according to different age groups (Table 2 
and Figure 2) showing the mean levels MBL2 of healthy controls and TB patients based on age groups. Age-
based analysis of variance (ANOVA) showed no differences between the age groups in both healthy controls (p= 
0.533) and TB cases (p=0.538). 
Table 1: MBL2 levels of study subjects by gender 
Population  TB Cases  Healthy Controls 
Total population 14.0 ± 13.92 19.9 ± 18.52 
Male  12.3 ± 13.93 15.5 ± 15.90 
Female  15.5 ± 14. 12 20.9 ± 18.80 
 
 
Fig 1: Mean MBL2 levels in TB Cases and Healthy Controls across study populations 
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Table 2: table showing MBL2 levels (ng/ml) of study subjects according to age group 
Age Group  TB Cases  Healthy Controls 
0-17 0.3 ± 0.00 21.4 ± 19.59 
18-35 13.7 ± 13.64 14.0 ± 18.34 
36-50 13.8 ± 13. 06 12.8 ± 15.36 
51-65 21.0 ± 17.60 18.9 ± 9.61 
66-80 N/A 41.8 ±0.00 
 
 
Fig 2: MBL2 levels in TB Cases and Healthy Controls based on age groups 
 
4. Discussion 
MBL is one of the major pathogen associated molecular patterns (PAMPs) molecule that binds to array of 
carbohydrates on the surfaces of micro-organisms (Turner, 2004; Neth et al., 2000; Jack & Turner, 2003; 
Presanis et al., 2003). As a serum complement factor, it plays a dominant role in first line defence through the 
lectin complement pathway (Kuipers et al., 2003; Jack & Turner, 2003). 
MBL is reported to interact with 3- and 4-hydroxyl groups of many sugars such as N-acetyl-D-glucosamine, 
mannose, N-acetyl-mannosine, fucose, mannoheptulose, sedoheptulose and glucose on micro-organisms (Turner, 
2004; Kawasaki et al., 1989) as well as lipoarabinomannan of mycobacterial cell wall (Chatterjee et. al., 1992). 
These observations were what informed the basis for this study.   
Adult individuals that are homozygous for all wild-type alleles have MBL levels of about 1400μg/l and 
those that are heterozygous for codon 54 variant have reduced levels of the protein between 26 and 396μg/l 
depending on the promoter polymorphisms present (Madsen et al.,1995). 
In a study in UK Caucasoid by Crosdale and Co-workers (2000), they found that in the low producing sub-
population, heterozygosity for codon 52 variants have lower serum MBL of 29.24μg/l than heterozygotes for 
codon 54 (65.51μg/l). Also in the population, they found that heterozygotes for codon 52 variant had a mean 
level of 601μg/l with the mean level for codon 54 heterozygotes being 297μg/l.   
From this study, healthy individuals had mean MBL levels of 19.9ng/ml which is far below the levels 
observed in Europeans conducted by Madsen and Colleagues (1995) and Crodale and Co-Workers (2000). 
Eventhough MBL levels in healthy individuals were higher than tuberculosis patients (14.0ng/ml), there was no 
significant difference between healthy controls and tuberculosis cases. There was no association of mannose 
binding lectin levels with tuberculosis.  The results from this study imply that mannose binding lectin is not an 
important factor in conferring resistance to tuberculosis infection in the population of Uyo Metropolis in Nigeria. 
A major limitation of this study was the lack of genetic screens to discover the occurrence of MBL genetic 
mutations in the population study. As a consequence, the design of therapeutic agents based on MBL levels 
would not be effective against the disease condition in this population.    
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